GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Debt-to-EBITDA

StemRIM (TSE:4599) Debt-to-EBITDA : N/A (As of Jan. 2025)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

StemRIM's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was 円0.00 Mil. StemRIM's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was 円0.00 Mil. StemRIM's annualized EBITDA for the quarter that ended in Jan. 2025 was 円0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for StemRIM's Debt-to-EBITDA or its related term are showing as below:

During the past 8 years, the highest Debt-to-EBITDA Ratio of StemRIM was 0.03. The lowest was -0.02. And the median was 0.00.

TSE:4599's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful Debt-to-EBITDA only.

StemRIM Debt-to-EBITDA Historical Data

The historical data trend for StemRIM's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Debt-to-EBITDA Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Debt-to-EBITDA
Get a 7-Day Free Trial 0.03 -0.01 - - -

StemRIM Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Jan25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - N/A

Competitive Comparison of StemRIM's Debt-to-EBITDA

For the Biotechnology subindustry, StemRIM's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where StemRIM's Debt-to-EBITDA falls into.


;
;

StemRIM Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

StemRIM's Debt-to-EBITDA for the fiscal year that ended in Jul. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1974.475
=0.00

StemRIM's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2025) EBITDA data.


StemRIM  (TSE:4599) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


StemRIM Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of StemRIM's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM Headlines

No Headlines